Undisclosed Immunology Programs

About BridGene Biosciences

BridGene Biosciences is an early-stage, platform-focused biotech leveraging its innovative IMTAC™ chemoproteomics technology to tackle undruggable disease targets. The company's approach allows for the systematic screening of small molecules against the entire proteome, identifying novel binding sites and chemical starting points for drug development. Its initial pipeline is concentrated in oncology, with programs targeting transcription factors and other difficult proteins. As a private company, BridGene's success hinges on validating its platform through internal pipeline advancement and strategic partnerships.

Therapeutic Areas

Other Immunological Disorders Drugs